Navigation Links
Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
Date:10/27/2011

of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

ADASUVE (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in adults with schizophrenia or bipolar disorder.  Alexza completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the ADASUVE NDA in December 2009.  In October 2010, the Company received a Complete Response Letter from the FDA regarding the application.  The Company completed an end-of-review meeting with the FDA in December 2010 and a Risk Evaluation and Mitigation Strategy (REMS) guidance meeting with the FDA in April 2011.  The ADASUVE NDA was resubmitted on August 4, 2011 and has a Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.  The ADASUVE NDA will be presented to an advisory committee on December 12, 2011.

In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer International, S.A.  Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.  Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011.  

For mo
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... 2010 UK based Trimega Laboratories is pleased to announce ... set by the prestigious Investors in People (IIP) Standard. ... Representative Quality Board of IIP and reflects the commitment and ... significant aspect of the achievement is that, as a ...
... and SYDNEY, Nov. 11, 2010 HeartWare International, Inc. ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that CEO Doug Godshall is scheduled to make ... Annual Healthcare Conference on Wednesday, November 17, at 1:15 ...
Cached Medicine Technology:IIP Recognition for Substance Abuse Testing Lab Trimega Laboratories 2HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference 2
(Date:4/22/2014)... person we all seem to know who we say is ... she isn,t unable to act but simply doesn,t want to., ... A study of nearly 4,000 college students in 19 countries ... making decisions and moving forward with life. Turns out that ... they just don,t like it as much as non-neurotics. Therefore ...
(Date:4/22/2014)... is available in German . ... of the University of Vienna and the Medical University of ... shown how double stranded RNA, such as viral genetic information, ... the immune response against viral infection, the protein ADAR1 moves ... modifies viral RNA to inhibit reproduction of the virus. But ...
(Date:4/22/2014)... their total brain size suggests they have more ... according to a new study of 36 species ... zebra finches. , Scientists at Duke University, UC ... research institutions collaborated on this first large-scale investigation ... study as the ability to inhibit powerful but ...
(Date:4/22/2014)... familiar trope in science fiction: In enemy territory, activate ... to make themselves invisible to the immune system. Now ... have mimicked these viral tactics to build the first ... , The results pave the way for smart DNA ... and more accurately than doctors can today; target drugs ...
(Date:4/22/2014)... researchers have found that the anxiety experienced with ... negatively impact a woman,s overall well-being. Their findings ... which was published online in the April 21, ... from 40 to 60 percent of women who ... will experience a false-positive mammogram. Such mammograms require ...
Breaking Medicine News(10 mins):Health News:Neurotics don't just avoid action: They dislike it 2Health News:How the body fights against viruses 2Health News:How the body fights against viruses 3Health News:Brain size matters when it comes to animal self-control 2Health News:Brain size matters when it comes to animal self-control 3Health News:Cloaked DNA nanodevices survive pilot mission 2Health News:Cloaked DNA nanodevices survive pilot mission 3Health News:False-positive mammogram anxiety has limited impact on women's well-being 2
... Nutrition Inc. Chooses ,it, Girl PR to help promote their ... ... "it" Girl Public relations, one of,the leading Public Relations ... of Optimal Nutrition Inc. (O.N.I.).,O.N.I. bestows a customized door-to-door organic ...
... Group, a life sciences,focused, corporate, investor and public ... as agency of record by Agile Therapeutics, of,Princeton, ... Donna LaVoie, President and CEO, commented, "LaVoie ... tactical execution to these,exciting companies as they accelerate ...
... Expand Agency ... Representation in Massachusetts -, WORCESTER, Mass., Nov. 19 ... writer of auto, home and,business insurance in Massachusetts, announced today ... enhanced auto product that will,deliver highly- competitive prices and innovative ...
... Wealth Measures: Three-Quarters Say Governments, Should Look Beyond ... BRUSSELS, Belgium, Nov. 19 Three-quarters of,people in ... and include health, social and environmental statistics in,measuring ... growth,alone is the most important measure. Around ...
... CorVel Corporation,(Nasdaq: CRVL ) today announced ... stock under the stock repurchase program previously approved,by ... the Board had approved a,1,500,000 share expansion to ... has repurchased 862,323 shares, with a remaining 637,677,shares ...
... ThalesNano Inc.,and the Christian Doppler Laboratory ... Graz today announced a scientific,collaboration on flow/microwave ... application of flow reactors for organic synthesis ... background in,continuous processing. ThalesNano and the Christian ...
Cached Medicine News:Health News:'it' Girl Public Relations Adds 'O.N.I.' New Organic Food Delivery Service to Its Lifestyle Division 2Health News:LaVoie Group Adds Two New Companies to Its Life Science Client Roster 2Health News:The Hanover Seeks to Cut Auto Rates by Up to 30 Percent or More; Shave Three Years Off State's Existing Six-Year Surcharge Period 2Health News:The Hanover Seeks to Cut Auto Rates by Up to 30 Percent or More; Shave Three Years Off State's Existing Six-Year Surcharge Period 3Health News:The Hanover Seeks to Cut Auto Rates by Up to 30 Percent or More; Shave Three Years Off State's Existing Six-Year Surcharge Period 4Health News:GLOBESCAN Survey for the BEYOND GDP Conference, European Parliament, Nov. 19th and 20th 2Health News:GLOBESCAN Survey for the BEYOND GDP Conference, European Parliament, Nov. 19th and 20th 3Health News:CorVel Corporation Announces Resumption of Stock Repurchases 2Health News:CorVel Corporation Announces Resumption of Stock Repurchases 3Health News:ThalesNano Inc. and the Christian Doppler Laboratory for Microwave Chemistry in Graz, Austria Collaborate on Flow Chemistry Technologies 2Health News:ThalesNano Inc. and the Christian Doppler Laboratory for Microwave Chemistry in Graz, Austria Collaborate on Flow Chemistry Technologies 3
... Single Use Loading Units With ... ILA™ 75 (Single Use Reloadable ... ,INDICATIONS The ILA™ 75 single-use ... for use in the resection, ...
... The Auto Suture™ GIA™ Reloadable Staplers ... application in abdominal, gynecological, pediatric and ... and creation of anastomosis. , ... and the SGIA™ Knifeless Stapler have ...
... Staplers are anastomotic staplers available in four ... to lumen diameter. The staplers permit tissue ... improve access and ease of use. The ... compression by adjusting the height of the ...
... ENDOPATH STEALTH Intraluminal Staplers are anastomotic ... proper matching of instrument to lumen diameter. ... detachable anvil head to improve access and ... surgeon to control tissue compression by adjusting ...
Medicine Products: